GlassScriptPhysician profile
Elena Sidorenko
NPI 1831281674
$13,490.18
in general payments reported to CMS, 2019-2025
40 companies · $2,694 in 2025
The $2,694 reported for 2025 was more than what 85% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $506 · 2020: $1,011 · 2021: $1,919 · 2022: $2,084 · 2023: $2,504 · 2024: $2,773 · 2025: $2,694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,971.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,970.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,231.37 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,080.84 | 2020-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $1,179.98 | 2019-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $1,033.52 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Gilead Sciences, INC. | $695.80 | 2020-2025 | |
| Lilly USA, LLC | $601.00 | 2023-2025 | Omvoh |
| Celgene Corporation | $562.18 | 2019-2024 | Zeposia |
| Qol Medical, LLC | $491.63 | 2020-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $350.44 | 2022-2025 | |
| Pfizer INC. | $340.15 | 2019-2025 | |
| Ardelyx, INC. | $335.38 | 2022-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $327.44 | 2022-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $254.72 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $254.32 | 2020-2024 | Linzess |
| Madrigal Pharmaceuticals | $216.64 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $202.77 | 2024-2025 | Vegzelma |
| Intercept Pharmaceuticals, INC. | $151.75 | 2021-2025 | Ocaliva |
| Ucb, INC. | $128.53 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $124.72 | 2021 | |
| Janssen Scientific Affairs, LLC | $112.43 | 2019 | |
| Daiichi Sankyo INC. | $104.61 | 2020-2022 | |
| Aimmune Therapeutics, INC. | $92.82 | 2024-2025 | Zenpep |
| Laborie Medical Technologies Corp. | $75.53 | 2023 | |
| Redhill Biopharma INC. | $70.02 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $68.78 | 2021-2022 | |
| Mylan Institutional INC. | $49.92 | 2023 | Hulio |
| Merck Sharp & Dohme LLC | $43.21 | 2023-2024 | Dificid |
| Ferring Pharmaceuticals INC. | $38.80 | 2020-2021 | |
| Amgen INC. | $38.05 | 2023 | Avsola, Amjevita |
| Echosens North America, INC. | $34.45 | 2024 | Fibroscan |
| Cook Medical LLC | $29.41 | 2019 | |
| Alfasigma USA, INC. | $29.14 | 2020 | |
| Sandoz INC. | $26.54 | 2023 | Hyrimoz |
| Lucid Diagnostics INC. | $19.16 | 2023 | |
| Capsovision, INC. | $18.64 | 2023 | Capsocam Plus |
| Endo Pharmaceuticals INC. | $16.80 | 2020 | |
| Organon LLC | $16.59 | 2023 | Renflexis, Hadlima |
| Exact Sciences Corporation | $15.22 | 2023 | Cologuard Collection Kit |
| Novo Nordisk INC | $14.19 | 2025 | Wegovy |
| Oxford Immunotec USA INC | $12.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elena Sidorenko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.